These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 21292861)
1. Categorical agreements and discrepancies of direct susceptibility tests in Acinetobacter from blood cultures. Couto VS; de Barros CR; Cerri ACSL; Perez LRR; Dias CAG J Med Microbiol; 2011 Jun; 60(Pt 6):863-864. PubMed ID: 21292861 [No Abstract] [Full Text] [Related]
2. In vitro activity of tigecycline against colistin-resistant Acinetobacter spp. isolates from Korea. Park YK; Choi JY; Song JH; Ko KS Int J Antimicrob Agents; 2009 Mar; 33(3):289-90. PubMed ID: 19091518 [No Abstract] [Full Text] [Related]
3. Impact of test methodology, media type and ion content on the susceptibility of Acinetobacter spp. to tigecycline. Qu J; Zong Z; Yu R; Hu T; Ye H; Lü X J Antimicrob Chemother; 2014 Jun; 69(6):1710-1. PubMed ID: 24481321 [No Abstract] [Full Text] [Related]
4. Comparison of three methods of determining the in-vitro susceptibilities of Acinetobacter baumannii isolates to imipenem. Pascual A; Martínez-Martínez L; Clavijo MJ; García-Perea MD; Perea EJ J Antimicrob Chemother; 1997 Nov; 40(5):742-3. PubMed ID: 9421332 [No Abstract] [Full Text] [Related]
5. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa. Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093 [No Abstract] [Full Text] [Related]
6. In vitro activities of ampicillin, sulbactam and a combination of ampicillin and sulbactam against isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolated in Chile between 1990 and 1998. Bello H; Domínguez M; González G; Zemelman R; Mella S; Young HK; Amyes SG J Antimicrob Chemother; 2000 May; 45(5):712-3. PubMed ID: 10797101 [No Abstract] [Full Text] [Related]
7. [Acinetobacter calcoaceticus, a potential pathogen with an increasing role in pathology]. Georgescu C; Neguţ M; Marinescu L; Călin C; Boboc F; Georgescu-Brăila M; Florescu DP; Trifan G Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1984; 29(4):333-9. PubMed ID: 6522946 [No Abstract] [Full Text] [Related]
8. IMP-1-producing carbapenem-resistant Acinetobacter ursingii from Japan. Endo S; Sasano M; Yano H; Inomata S; Ishibashi N; Aoyagi T; Hatta M; Gu Y; Yamada M; Tokuda K; Kitagawa M; Kunishima H; Hirakata Y; Kaku M J Antimicrob Chemother; 2012 Oct; 67(10):2533-4. PubMed ID: 22733654 [No Abstract] [Full Text] [Related]
9. The susceptibility to tigecycline of Acinetobacter spp. may vary depending on the methodology used. Zárate MS; Serruto G; Smayevsky J Int J Infect Dis; 2010 Sep; 14 Suppl 3():e351-2. PubMed ID: 20031463 [No Abstract] [Full Text] [Related]
10. [Is sulbactam really the answer for treatment of infections caused by multiresistant strains of Acinetobacter spp.?]. Casellas JM; Dana R Enferm Infecc Microbiol Clin; 1997; 15(6):335-6. PubMed ID: 9376409 [No Abstract] [Full Text] [Related]
11. [Ecology and the antibiotic sensitivity of hospital strains of Acinetobacter]. Gladshteĭn AI; Tuzova ZG; Kovalenko ON; Petrakov AA; Mel'nikova VM Antibiot Med Biotekhnol; 1987 Mar; 32(3):195-8. PubMed ID: 3579246 [TBL] [Abstract][Full Text] [Related]
14. Tigecycline disk diffusion breakpoints of Acinetobacter spp.: a clinical point of view. Curcio D; Fernández F; Jones RN; Ferraro MJ; Reller LB; Schreckenberger PC; Sader HS J Clin Microbiol; 2007 Jun; 45(6):2095; author reply 2095-6. PubMed ID: 17548459 [No Abstract] [Full Text] [Related]
15. First isolation of Acinetobacter johnsonii co-producing PER-2 and OXA-58 β-lactamases. Rodríguez CH; Nastro M; Dabos L; Barberis C; Vay C; Famiglietti A Diagn Microbiol Infect Dis; 2014 Dec; 80(4):341-2. PubMed ID: 25294301 [No Abstract] [Full Text] [Related]
16. [Identification and sensitivity of acinetobacter sp isolated from clinical specimens and hospital environment]. Martínez MA; Pinto ME; Giglio MS; Pommier J; Muñoz LM Rev Med Chil; 1992 Nov; 120(11):1267-72. PubMed ID: 1340947 [TBL] [Abstract][Full Text] [Related]
17. Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period. Ruiz J; Núñez ML; Pérez J; Simarro E; Martínez-Campos L; Gómez J Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):292-5. PubMed ID: 10385020 [TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of NDM-1-producing Acinetobacter pittii isolated from Turkey in 2006. Roca I; Mosqueda N; Altun B; Espinal P; Akova M; Vila J J Antimicrob Chemother; 2014 Dec; 69(12):3437-8. PubMed ID: 25096072 [No Abstract] [Full Text] [Related]
19. Infection due to Mima-Herellea. Suwanraks C; Jayanetra P; Prachaktham R; Tejavej A J Med Assoc Thai; 1971 Nov; 54(11):849-57. PubMed ID: 5128925 [No Abstract] [Full Text] [Related]
20. [Microbiological aspects and problems of antibiotic resistance in sepsis due to Acinetobacter (Mimae)]. Robert L; Piersantelli N Pathologica; 1971; 63(925):281-90. PubMed ID: 5155560 [No Abstract] [Full Text] [Related] [Next] [New Search]